SCARLET (SWOG S2212)
Tests whether the anthracycline can be dropped from TNBC pre-surgery treatment without losing effect.
Non-inferiority design on EFS; would reduce cardiotoxicity and leukaemia risk. Part of the TIL-informed de-escalation movement.
Setting
Stage II-III TNBC: anthracycline-free carboplatin/docetaxel + pembrolizumab vs KEYNOTE-522 regimen
Phase
Phase 3
Sponsor
SWOG / NCI
Registry
Enrolled
2400
Replication
Ongoing; no results.